These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 30575943

  • 1. Effect of siglidine on glucose lipid metabolism and the expression of iNOS and GLP-1 receptors in diabetic rats.
    Zhang HY, Li Y, Zhong YH, Ruan LB, Yang TR, Yin HP.
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8984-8989. PubMed ID: 30575943
    [Abstract] [Full Text] [Related]

  • 2. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
    Ren X, Liu G, Wang Y, Zhang W, Xue F, Li R, Yu W.
    Pharmacology; 2017 Dec; 100(1-2):1-13. PubMed ID: 28329747
    [Abstract] [Full Text] [Related]

  • 3. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
    Ramírez E, Picatoste B, González-Bris A, Oteo M, Cruz F, Caro-Vadillo A, Egido J, Tuñón J, Morcillo MA, Lorenzo Ó.
    Cardiovasc Diabetol; 2018 Jan 11; 17(1):12. PubMed ID: 29325553
    [Abstract] [Full Text] [Related]

  • 4. CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin.
    Coskun ZM, Koyuturk M, Karabulut S, Bolkent S.
    Pharmacol Rep; 2017 Aug 11; 69(4):822-829. PubMed ID: 28599244
    [Abstract] [Full Text] [Related]

  • 5. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-β/Smad signal pathway.
    Li L, Lian X, Wang Z, Zheng J, Liu J, Chu Y, Teng Y, Zhang Z.
    Pharmazie; 2019 Apr 01; 74(4):239-242. PubMed ID: 30940309
    [Abstract] [Full Text] [Related]

  • 6. Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin.
    Manaer T, Yu L, Zhang Y, Xiao XJ, Nabi XH.
    J Ethnopharmacol; 2015 Jul 01; 169():269-74. PubMed ID: 25922265
    [Abstract] [Full Text] [Related]

  • 7. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
    Karabulut S, Coskun ZM, Bolkent S.
    Pharmacol Rep; 2015 Oct 01; 67(5):846-53. PubMed ID: 26398375
    [Abstract] [Full Text] [Related]

  • 8. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
    Marques C, Gonçalves A, Pereira PMR, Almeida D, Martins B, Fontes-Ribeiro C, Reis F, Fernandes R.
    Life Sci; 2019 Oct 01; 234():116738. PubMed ID: 31398418
    [Abstract] [Full Text] [Related]

  • 9. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
    Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ, Zhou Q, Wei W, Zhu HQ, Wang Y.
    Int J Mol Med; 2016 Jun 01; 37(6):1558-66. PubMed ID: 27122056
    [Abstract] [Full Text] [Related]

  • 10. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats.
    Eitah HE, Maklad YA, Abdelkader NF, Gamal El Din AA, Badawi MA, Kenawy SA.
    Toxicol Appl Pharmacol; 2019 Feb 15; 365():30-40. PubMed ID: 30576699
    [Abstract] [Full Text] [Related]

  • 11. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
    Liu YS, Huang ZW, Wang L, Liu XX, Wang YM, Zhang Y, Zhang M.
    J Pharmacol Sci; 2015 Mar 15; 127(3):260-74. PubMed ID: 25837922
    [Abstract] [Full Text] [Related]

  • 12. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
    Zhou Y, Wang H, Man F, Guo Z, Xu J, Yan W, Li J, Pan Q, Wang W.
    Cardiovasc Drugs Ther; 2018 Dec 15; 32(6):541-552. PubMed ID: 30328028
    [Abstract] [Full Text] [Related]

  • 13. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y.
    Hypertension; 2012 Sep 15; 60(3):833-41. PubMed ID: 22868389
    [Abstract] [Full Text] [Related]

  • 14. Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.
    Badole SL, Bagul PP, Mahamuni SP, Khose RD, Joshi AC, Jangam GB, Ghule AE, Raut CG, Khedkar VM, Coutinho EC.
    Chem Biol Interact; 2013 Apr 25; 203(2):530-41. PubMed ID: 23466488
    [Abstract] [Full Text] [Related]

  • 15. Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats.
    Badole SL, Chaudhari SM, Bagul PP, Mahamuni SP, Khose RD, Joshi AC, Raut CG, Zanwar AA.
    PLoS One; 2013 Apr 25; 8(8):e72817. PubMed ID: 24023648
    [Abstract] [Full Text] [Related]

  • 16. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balance.
    Mietlicki-Baase EG, McGrath LE, Koch-Laskowski K, Krawczyk J, Pham T, Lhamo R, Reiner DJ, Hayes MR.
    Physiol Behav; 2017 May 01; 173():9-14. PubMed ID: 28119159
    [Abstract] [Full Text] [Related]

  • 17. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J, Miao JJ, Sun XY, Yu JY.
    J Ethnopharmacol; 2016 Aug 02; 189():238-49. PubMed ID: 27224243
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.
    Xu J, Wang J, Cheng Y, Li X, He M, Zhu J, Han H, Wei G, Kong H, Xie W, Wang H, Zuo X.
    Biomed Res Int; 2018 Aug 02; 2018():1864107. PubMed ID: 29607314
    [Abstract] [Full Text] [Related]

  • 19. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
    Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F, Reis F.
    Exp Diabetes Res; 2011 Aug 02; 2011():162092. PubMed ID: 22203828
    [Abstract] [Full Text] [Related]

  • 20. Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model.
    Liu Y, Kang J, Gao H, Zhang X, Chao J, Gong G, Yuan H, Xie C.
    Endocr Metab Immune Disord Drug Targets; 2019 Aug 02; 19(5):622-631. PubMed ID: 30799801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.